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 Cow’s milk protein allergy (CMPA) is a common allergic response in infants and 
young children. This report presents the key aspects of CMPA: clinical features, 
pathogenesis, symptoms, epidemiology, genetic and environmental factors, diagnosis, 
and treatment. Current research of methods for modulating allergic responses is also 
presented. One avenue being studied is the effect of omega-3 polyunsaturated fatty acids 
(PUFAs) on CD4+ T cell differentiation and regulation. Omega-3 PUFAs have been 
found to modify the plasma membrane organization of CD4+ T cells, thus affecting key 
signaling pathways involved in the manifestation of allergic diseases. The specific 
pathways and molecules in CD4+ T cells that are downregulated via omega-3 PUFA 
incorporation are presented. A clinical case study detailing the manifestations of this 
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 Cow’s milk protein allergy (CMPA) is an immunological adverse reaction to 
cow’s milk protein and usually presents as the first food allergy in children, ages 
newborn to 4 years old. The proteins in cow’s milk that usually elicit a reaction are: α-
lactalbumin, β-lactoglobulin, and casein (Solinas, Corpino, Maccioni, & Pelosi, 2010). 
The allergy can present as IgE or non-IgE mediated and depending on either 
characteristic, symptoms like anaphylaxis, respiratory reactions, or gastrointestinal 
reactions can manifest in affected children (Solinas et al., 2010).  The proteins in cow’s 
milk initiate a cascade of reactions that affect a number of different types of cells in the 
immune system. The allergy involves antigen specific T cells, T regulatory cells, 
cytokines from different kinds of T cells, B lymphocytes, and mast cells (Coco, Andrea 
Domenico, Vitaliti, Cimino, & Lionetti, 2012). There are a number of methods utilized in 
diagnosing CMPA, most commonly an oral food challenge, a skin test, or an 
immunoassay (Jarvinen-Seppo MD PhD, 2013). Current treatments for CMPA require 
changing of the child’s diet to eliminate milk proteins until they overcome the allergy. 
There is ongoing research for other treatments of CMPA, including modulation of the 
immune system via nutritional intervention with polyunsaturated fatty acids (PUFAs) 
(Thang, Boye, Shi, & Zhao, 2013). 
I. Clinical Features 
Cow’s milk protein allergy usually manifests during the first few months of 
life. After the introduction of a cow’s milk-based formula or the ingestion of breast 
milk from a mother who consumes cow’s milk, the infant presents with CMPA within 
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days or weeks (Jarvinen-Seppo MD PhD, 2013). CMPA can be categorized as an 
Immunoglobulin E (IgE) mediated syndrome or non-IgE mediated. Some cases of 
CMPA can also present both characteristics of IgE and non-Ige, called mixed IgE and 
non-IgE CMPA. The IgE mediated reaction represents a classic allergic reaction and 
yields immediate clinical reactions (Solinas et al., 2010). The infant can present with 
reactions in the skin, oropharyngeal tract, upper and lower respiratory tracts, 
gastrointestinal tracts, and the cardiovascular system within hours after exposure to 
cow’s milk antigens (Jarvinen-Seppo MD PhD, 2013). Non-IgE mediated reactions 
also affect the same systems of the body as IgE-mediated reactions; however, non-
IgE mediated reactions are delayed, and infants can present with symptoms within 
days or weeks after the initial exposure.  
II. Pathogenesis 
Ig-E mediated CMPA consists of a sensitization phase and an activation phase 
(Coco et al., 2012). In sensitization, IgE antibodies against cow’s milk proteins are 
secreted and bind to the surface of mast cells and basophils awaiting the next 
exposure to cow’s milk. In subsequent exposures, the activation phase starts when the 
IgE antibodies that were already joined to mast cells and basophils bind to the 
allergenic epitopes of α-lactalbumin, β-lactoglobulin, or casein (Coco et al., 2012). 
This causes a release of inflammatory mediators that then manifest in the clinical 
symptoms of CMPA. 
There is less understanding of the mechanisms regarding non-IgE mediated 
CMPA, but has a number of different proposed theories. One reaction involves the 
binding of the cow’s milk antigen to the cell surface, which induces different 
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immunoglobulin classified antibodies (IgG, IgM, IgA) to disturb the cell membrane 
and cause cell death (Solinas et al., 2010). Another reaction involves IgG, IgM, and 
IgA antibodies becoming trapped in small blood vessels, while another reaction may 
be mediated by sensitized T-lymphocytes (Solinas et al., 2010). Other general ideas 
of non-IgE mediated CMPA include: reactions facilitated by helper T cells (Th1) and 
interactions between T cells, mast cells, and neurons (Coco et al., 2012). 
As a part of the pathogenesis of CMPA, the different kinds of T cells and their 
roles in allergies are currently being studied. Naïve T cells can be sensitized and 
differentiate in to Th2 lymphocytes that then secrete IL-4, IL5, IL10, and IL13, 
cytokines that promote the production of IgE and amplify the inflammatory response 
(Coco et al., 2012). A dysfunction of Treg cells (regulatory T cells) could also explain 
the lack of tolerance for milk proteins as these cells produce cytokines (TGF-β and 
IL-10) that regulate the immune system and dampen T cell responses (Coco et al., 
2012).  Studies are also focusing on CD4+, CD25+, and Foxp3+ T cells, as they are 
important in suppressing T cell proliferation (Coco et al., 2012). 
III. Symptoms 
CMPA generates a variety of symptoms in infants afflicted with the disease. 
Immediately after the consumption of milk proteins, if the child presents with 
symptoms such as: frequent regurgitation, vomiting, hives, swelling of the lips or eye 
lids, wheezing, and a dry cough, then the child can be suspected of having CMPA. 
Symptoms from CMPA do not always come about immediately. Late onset symptoms 
include: diarrhea, blood in the stools, iron deficient anemia, gastroesophageal reflux, 
and colic (episodes of crying for more than 3 hours a day) over a three-week period 
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(Solinas et al., 2010).  
The classification of CMPA (IgE, non-IgE, and mixed IgE and non-IgE) can 
also determine a more specific list of symptoms. IgE-mediated CMPA causes 
anaphylaxis, angioedema, as well as oropharyngeal and gastrointestinal reactions. 
Non-IgE mediated CMPA causes enterocolitis where the child presents with severe 
vomiting and diarrhea. The child can also have gastroesophageal reflux and 
constipation. Non-IgE mediated CMPA may also cause Heiner syndrome, a 
pulmonary disease that presents the child with cough, fever, wheezing, and nasal 
congestion. Mixed IgE and non-IgE reactions can cause atopic dermatitis (eczema), 
asthma, or eosinophilic gastrointestinal disorders (inflammation of the esophagus by 
eosinophils) (Jarvinen-Seppo MD PhD, 2013). 
There are rare symptoms associated with severe cases of CMPA. These 
include: severe atopic dermatitis, hypoalbuminemia (low blood albumin levels), 
failure to thrive, and anemia due to rectal bleeding and loss of protein. 
IV. Epidemiology 
Cow’s milk protein allergy is the most common food allergy in young 
children. It makes up about 9% of total reported cases of food allergies (Gaudin et al., 
2008). It affects about 2% of children under four years of age (Jarvinen-Seppo MD 
PhD, 2013). In one-year old children, the prevalence of the disease is higher with a 
2.2-2.8% initial occurrence compared to a 0.6% occurrence in three-year old children 
(Jarvinen-Seppo MD PhD, 2013).  The prevalence of CMPA in adults is much less 
common with 0.1-0.3% of adults with the confirmed allergy. Cow’s milk is one of the 
most common foods responsible for anaphylactic reactions. A pediatric allergy clinic 
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that focused on food allergies reported a 40% incidence of CMPA in their patients 
(Jarvinen-Seppo MD PhD, 2013). 
Children usually outgrow Cow’s milk protein allergy.  51% of infants develop 
a tolerance within the first two years of life and if it persists for longer, 80% of 
children will develop a tolerance within 3-4 years of age (Coco et al., 2012). Non-IgE 
mediate CMPA is usually resolved more quickly than IgE-mediated CMPA. IgE-
mediated CMPA can persist until late childhood or adolescence, but 64% of such 
children outgrow the allergy by 12 years old (Jarvinen-Seppo MD PhD, 2013). 
V. Genetic and Environmental Factors 
It has been reported that individuals genetically predisposed to developing 
CMPA are more likely to sensitize T cells to the Th2 response that releases 
inflammatory cytokines (Beyer et al., 2002). Such cytokines are responsible for much 
of the clinical manifestations of CMPA. For individuals that have been diagnosed 
with CMPA, they can have genetic predispositions to developing a tolerance to the 
allergy more easily. Such factors include: naturally low initial levels of milk-specific 
IgE, faster rate of decline of milk IgE, and lack of allergic rhinitis (inflammation of 
the mucous membrane of the nose) or asthma (Coco et al., 2012).  
Environmental factors associated with CMPA include the initial exposures of 
children to the cow’s milk proteins, which can come from ingestion of milk proteins 
in formula or in breast milk. It is theorized that the industrialization of societies has 
decreased the microbial exposure infants receive, which plays a factor in Treg cell 
dysfunction and thus promotes allergic disorders (Rook & Brunet, 2005). No other 





To diagnose CMPA, the clinical history of the child as well as laboratory tests 
are used with a timetable or an outlined process of diagnosis also being followed 
(Figure 1). An oral food challenge is mostly utilized for diagnoses, specifically a 
double-blind, placebo-controlled food challenge, but an open food challenge is used 
when the child is younger (Solinas et al., 2010). The suspected food is eliminated, 
then used to challenge the child, and then re-eliminated. In breastfed infants, the 
mother avoids ingesting cow’s milk while formula fed infants are given formula 
without milk proteins. If the CMPA is suspected to be mild to moderate, the 
elimination phase starts with a therapeutic formula with no milk proteins for 2-4 
weeks. If symptoms disappear after this period, then an open challenge with formula 
containing milk proteins is performed (Solinas et al., 2010). If the child does not 
develop symptoms after the repeated challenge, a one-week follow-up is done which 
then determines if the child can resume a normal diet.  
A skin test can also be used to diagnose CMPA. A portion of the infant’s skin 
is exposed to commercial cow’s milk extract. A wheal diameter of 8mm in children 
over 2 years old and 6mm in children under 2 years old indicates CMPA (Jarvinen-
Seppo MD PhD, 2013). More specific guidelines for wheal diameters in infants report 
different measurements for the different milk proteins; 12mm for α-lactalbumin, 
10mm for β-lactoglobulin, and 9mm for casein (Solinas et al., 2010). Immunoassays 
measuring the amount of specific IgE antibodies can also be used to diagnose 
children with the cut-off level of 0.35 U/ml (Solinas et al., 2010). 
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Figure 1 Diagnosis and management of CMPA. Figure was taken from 
Solinas et al, a review of Cow’s milk protein allergy. 
VII. Treatment 
To treat cow’s milk protein allergy, removal of milk and milk products from 
the diet will prevent exposure to the antigenic proteins. There are three types of infant 
formula that can be used to replace a diet containing milk: soy, extensively 
hydrolyzed, and amino acid. Soy formula is usually the first alternative to milk but 
around 10% of children with IgE-mediated CMPA and 60% of children with non IgE-
in predicting the prognosis and the time interval until
the next challenge. A negative skin prick test and RAST
result reduces the risk of a severe acute reaction during
challenge.
In children !2 years of age a skin test wheal diameter
"6 mm for milk, and in children 42 years of age a skin test
wheal diameter "8 mm will have PPV 490% for a positive
food challenge [12].
In infants, a skin prick test with a reaction with a large
diameter (12 mm for alfa-lactalbumin, 9 mm for casein,
10 mm for beta-lactoglobulin, and 15 mm for fresh cow’s
milk) will have PPV 95% for a positive food challenge [13].
In these confirmatory CMP challenge can be postponed
until the child shows a reduced reaction in the prick tests
for CMP and specific IgE.
In breast-fed infants, most frequent symptoms of CMPA
are atopic dermatitis, vomiting, diarrhea, constipation,
blood in stool, gastro esophageal reflux, and colic. We have
infant with mild symptoms and infant with severe
symptoms. In infants with mild symptoms, elimination
diet in mother is not indicated. In infant with moderate-
severe symptoms, CMP and eggs should be eliminated in
mother diet for 2–4 weeks. The mother will require
calcium supplements during the elimination diet [2].
If symptoms in infants improve or disappear during the
elimination diet, one food per week could be reintroduced
into the mother’s diet. If symptoms do not reappear during
food reintroduction the diet could be discontinued; if
symptoms reappear during food reintroduction the mother
diet should be continued until weaning [2].
If symptoms in infants do not improve, a normal mother
diet could be reintroduced.
When it is necessary, breast feeding should be supple-
mented with hydrolyzed formula.
Solid foods free of CMP until 9–12 months and for at
least 6 months [2].
Therapy
The general treatment for CMPA is dietary and consists of
eliminating milk and milk products from the diet to avoid
exposure to the impli ate allergens.
Three types of infant formula (soy, extensively hydrolyzed
and amino acid) may be appropriate for treating CMPA
[6,14,15].
Selection of a formula depends on the allergy syndrome
to be treated.
Soy preparations, although historically the first pre-
scribed, are not perfectly qualified to the nutritional needs
of children. Furthermore, despite the absence of protein
homology and cross-allergy, around 10% of IgE-mediated
and 60% of non-IgE-mediated allergic children are also
allergic to soy. Soy protein is not hypoallergenic. The
incidence of soy allergy in soy formula-fed infants is
comparable to that of CMPA in cow’s milk formula-fed
Figure 1. Flow chart for the diag osis and management of CMPA in formula-fed infants.
78 C. Solinas et al.
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mediated CMPA have been shown to have an allergy to soy (Solinas et al., 2010). 
Extensively hydrolyzed formula is the first choice for infants under 6 months of age. 
It is also used to treat infants who have presented with non-anaphylactic symptoms, 
enterocolitis (inflammation of the digestive tract), atopic eczema, and gastrointestinal 
symptoms. If there is a poor response to extensively hydrolyzed formula, amino acid 
formula is then chosen. Amino acid formula is also used for infants who have severe 
CMPA or have been diagnosed with anaphylaxis or eosinophilic oesophagitis 
(inflammation of the esophagus) (Solinas et al., 2010). If the allergy persists past 
infancy, any food that contains traces of milk must be avoided.  
For infants that maintain breast-feeding, the mother will have to avoid milk, 
milk products, and eggs until the infant is weaned. The mother is usually advised to 
take calcium supplements during this time (Solinas et al., 2010). 
Body of Review 
 Current research on the modulation of the allergic response in CMPA exploits 
CD4+ T cells and their mechanism of action in allergies. CD4+ T cells can differentiate 
into various kinds of T cells. Notable for CMPA, is the differentiation of CD4+ T cells 
into type 1 helper T cells (Th1) and type 2 helper T cells (Th2). It has been noted that the 
Th2 response is elevated in food allergies and asthma (Thang et al., 2013). Th2 cells 
release the inflammatory cytokines: interleukin (IL)-4, IL-5, and IL-13, which are 
responsible for the activation of eosinophils and mast cells as well as the production of 
IgE (Jang, Lim, Lee, & Park, 2013). Such characteristics are responsible for the clinical 
manifestations of CMPA. Thang et al also noted that a shift from Th2 responses to Th1 
responses helps modulate allergic responses. Thang and his team attributed this outcome 
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to the role of Th1 cytokines. Th1 cells produce an anti-inflammatory cytokine, IL-10, as 
well as a cytokine essential for down-regulation of airway hyper-responsiveness, IL-
12p40 (Thang et al., 2013). Th1 cells also produce the chemokine MCP-1, which was 
reported to be found at higher levels in children who had overcome CMPA (Glez, Franco, 
& Matheu, 2012). A shift to Th1 responses seems to modulate allergic responses and one 
factor responsible is the intervention of omega-3 polyunsaturated fatty acids (Thang et 
al., 2013). 
 Polyunsaturated fatty acids (PUFAs) are fatty acids with at least one double bond 
in their backbone. There has been much research on omega-3 and omega-6 PUFAS and 
their effects on different areas of the human body and of human diseases. Omega-3 
PUFAs have been found to have anti-inflammatory and anti-proliferative effects while 
omega-6 PUFAs have shown the opposite (Thang et al., 2013). PUFAs are under research 
for their effects on allergic diseases. It has been theorized that PUFAs can affect allergies, 
such as CMPA, through the disruption of CD4+ T cells, thus affecting the mechanism 
and differentiation explained above that play a large role in CMPA. 
Conclusions 
Though a rather simple disease that is mostly outgrown, Cow’s milk protein 
allergy remains one of the most common food allergies as well as the first allergy infants 
acquire. CMPA presents with many different symptoms that at first, can be difficult to 
diagnose as a simple food allergy. Research for new, better diagnostic tools as well as 





Literature Review: Omega-3 PUFAs alter the plasma membrane molecular organization 




 Mostly diagnosed in infants and young children, Cow’s Milk Protein Allergy is an 
immunological reaction to the proteins found in cow’s milk: α-lactalbumin, β-
lactoglobulin, and casein (Solinas, Corpino, Maccioni, & Pelosi, 2010). One pathway that 
characterizes milk protein allergy, and most other food allergies, involves CD4+ T cells. 
Activation of CD4+ T cells is essential to the development of immune responses and they 
are reliant on signal cascades through the plasma membrane in order to complete the 
activation steps of the T cell (Brix et al., 2010).  In order to target T cell activation, 
research has looked to the tampering of the cells’ plasma membranes. Numerous studies 
have proposed that omega-3 polyunsaturated fatty acids alter the plasma membrane 
organization of a number of cells, notably CD4+ T cells (Brix et al., 2010)(Shaikh, Jolly, 
& Chapkin, 2012)(Stulnig et al., 2001)(Jang, Lim, Lee, & Park, 2013). Omega-3 
polyunsaturated fatty acids are a class of PUFAs that have a double bond three carbons 
away from the terminal end of their backbone. The altering of the plasma membrane of 
CD4+ T cells interrupts the signaling needed for activation of the cells as well as the 
production of cytokines responsible for allergic responses such as CMPA (Brix et al., 
2010).  Figure 2 shows the mechanism in which omega-3 PUFAs affect CD4+ T cell 
activation. First, a CD4+ T cell synapses with an antigen-presenting cell, which then 
induces activation of the T cell. It is proposed that omega-3 PUFAs increase the 
molecular order of lipid rafts in the plasma membrane, which subdues the recruitment of 
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signaling proteins for T cell activation (Shaikh et al., 2012). Lipid rafts are “transient 
sphingolipid/cholesterol assemblies…that compartmentalize signaling proteins” (Shaikh 
et al., 2012).    The second messengers: PIP2 and DAG, as well as the proteins: PLC-1, 
PKCθ, F-actin, and NF-κB, are all involved in CD4+ T cell activation and are suppressed 
by the incorporation of omega-3 PUFAs into the plasma membrane (Shaikh et al., 2012).  
Nutritional intervention with PUFAs holds promise as a method to modulate 

















Figure 2. Omega-3 PUFAs target the plasma membrane organization of lipid rafts of 
CD4+ T cells. Red circles represent omega-3 PUFAs targeting the cell. Figure taken 
from Shaikh et al (Shaikh et al., 2012). 
 
Methods and Results 
Signaling proteins of T cells are displaced upon treatment with Omega-3 PUFA 
While it was previously observed that omega-3 PUFAs affect T cell activity, the 
method of disruption needed further confirmation. Stulnig et al studied the in vitro effects 
Fig. 2. n!3 PUFAs increase lipid raft molecular order and suppress the recruitment and activation status of signaling proteins in the CD4+ T cell synapse. T
cell activation results in an increase in lipid raft molecular order following the formation of the T cell – antigen presenting cell dependent immunological
synapse. Green circles indicate cholesterol-enriched liquid ordered domains, which stabilize at the immunological synapse. Red circles indicate n!3 PUFA-























Fig. 1. n!3 PUFAs disrupt cholera toxin induced clustering of GM1 molecules on the outer leaflet of the B cell plasma membrane. (A) Sample images of
naïve B220+ B cells isolated from a C57BL/6 mouse fed a control diet (CD) or a diet enriched in a high dose of n!3 PUFAs. (B) Quantification of cholera toxin
induced clusters. Data are from a recent study on n!3 PUFAs and rafts by the Shaikh lab (Rockett et al., 2011).
S.R. Shaikh et al. / Molecular Aspects of Medicine 33 (2012) 46–54 49
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of omega-3 PUFAs on T cells’ signaling proteins by observing Jurkat T cells, 
immortalized human T cells, treated with the omega-3 PUFA, eicosapentanoic acid 
(20:5), and the control, stearic acid (18:0). Figure 3 shows a quantitative analysis of 
immunoblots done to measure the levels of proteins, Lck and LAT. The signaling 
proteins Lck and the transmembrane adaptor LAT, are members of the Src family 
kinases, which are tyrosine kinases that phosphorylate the tyrosine residues of other 
proteins (Stulnig et al., 2001). Compared to the control, the signaling proteins, Lck and 
Fyn (Fyn not shown in figure) as well as LAT, were displaced at a higher percentage 
from T cell membranes when treated with eicosapentanoic acid and the displacement of 
such kinases downregulates T cell differentiation (Stulnig et al., 2001). 
Stulnig et al also investigated whether the displacement of these proteins results 
from if omega-3 PUFAs alter the lipid raft environment or through S-acylation of 
proteins by omega-3 PUFAs. S-acylation is the targeting of transmembrane and 
intracellular proteins to membrane domains by acylation with fatty acyl moieties, such as 
palmitoyl residues (Stulnig et al., 2001). Stulnig et al reasoned that if omega-3 PUFAs 
displace proteins via S-acylation, then proteins that are already acylated with palmitate 
should not be affected by eicospentanoic acid. A group of Jurkat T cells were labeled 
with [3H] palmitate and Figure 3 shows that both non-labeled and [3H] palmitate-labeled 
proteins were displaced from the membrane; suggesting that omega-3 PUFAs alter the 























Figure 3. Percent displacement of Lck and LAT in Jurkat T cells. Immortalized human 
T cells (Jurkat T cells) were treated with stearic acid (18:0) and eicosapentanoic acid 
(20:5) and immunoblotted for protein levels. Black bars represent unlabeled proteins 
while gray bars represent [3H] palmitate labeled proteins. Figure taken from Stulnig, et 
al. (Stulnig et al., 2001). 
 
Activation and maturation of T cells are downregulated with omega-3 PUFAs 
To corroborate other studies’ in vitro findings of omega-3 PUFAs affecting T 
cells, Jang et al studied the effects of omega-3 PUFAs on CD4+ T cells of mice. Jang et 
al used Fat-1 transgenic mice, which have higher levels of omega-3 PUFAs in their 
organs and tissues. They prepared cultures of CD4+ T cells from the spleens and lymph 
nodes of the Fat-1 mice for evaluation. Figure 4 A and B shows a quantitative analysis of 
flow cytometry experiments, which measured the activation of T cells in mice. After a 48 
hour culture, cells were permeabilized and stained for flow cytometry, which then 
analyzed the number of stained cells activated with anti-CD69 and anti-CD25 antibodies 
to measure the percentage of CD69+ and CD25+ cells in Fat-1 transgenic mice (Jang et 
al., 2013). The cells showed lower levels of CD69+ and CD25+ cells, which are markers 
of T cell activation (Jang et al., 2013). The decreased levels of CD69+ and CD25+ in 
DISCUSSION
PUFAs inhibit T cell signaling most probably by displacing
proteins that are palmitoylated under physiological conditions
from lipid rafts. This displacement may principally be due to
altered protein acylation and/or altered raft lipid environment.
By analyzing raft lipid fatty acyl composition and membrane
subdomain distribution of palmitoylated proteins, we provide
ample evidence that altered raft lipid composition underlies the
displacement of proteins from lipid rafts in PUFA-treated T
cells.
PUFAs were highly enriched not only in bulk membranes but
also in rafts following PUFA treatment of T cells. Inclusion of
unsaturated fatty acids in model membranes greatly reduces
raft formation (26) resulting in detergent solubility of incorpo-
rated proteins (15, 44). Interestingly, raft lipids also contain
some PUFAs under physiological conditions (18), and distinct
PUFAs, e.g. arachidonic acid, were even enriched in rafts com-
pared with bulk membranes (Table I). Changes in lipid compo-
sition induced by treatment with polyunsaturated eicosapen-
taenoic acid were markedly mitigated in rafts compared with
bulk membranes, indicating that cells aim at maintaining raft
structures by providing a saturated fatty acyl environment
through yet unresolved compensatory mechanisms. Such par-
tial compensation was particularly evident in the significantly
minor incorporation of PUFAs and the concomitant increased
content of saturated palmitic (16:0) and stearic acid (18:0)
resulting in a markedly lower unsaturation index in rafts com-
pared with the bulk membranes of PUFA-treated T cells (Table
I). Nevertheless, incorporation of PUFAs resulted in a consid-
erable 42% increase in unsaturation in raft acyl chains of
membranes from PUFA-treated compared with control-treated
T cells.
Acyl moieties of proteins partition in the cytoplasmic leaflet
of the membrane lipid bilayer. Lipid alterations in the cytoplas-
mic lipid leaflet of membrane rafts would hence be particularly
effective in displacing palmitoylated proteins. In addition,
changes in fatty acyl composition of exoplasmic leaflet lipids
(sphingomyelin and phosphatidylcholine) could contribute to
the displacement of palmitoylated proteins from membrane
rafts by interdigitation of acyl chains with cytoplasmic leaflet
lipids or protein acyl moieties (16). Notably, the cytoplasmic
leaflet of rafts incorporated significant amounts of PUFAs as
shown by altered fatty acyl composition of raft phosphati-
dylethanolami e which predominantly resides in the cytoplas-
mic leaflet of the membrane bilayer (41) (Table II). Interaction
of ph spholipid acyl chains with cholesterol is required to
maintain organization of membrane rafts in a liquid-ordered
phase particularly in the cytoplasmic lipid leaflet that lacks
sphingolipids (16). Raft cholesterol content was unaltered by
PUFA treatment of T cells (Table I). However, the increase in
lipid order induced by cholesterol highly depends on acyl chain
unsaturation of phospholipid species in the absence of sphin-
golipids (45). The cholesterol-induced lipid order is particularly
decreased in phosphatidylethanolamine and phosphatidyl-
serine when substituted at its sn-2 position with PUFA com-
pared with oleic acid (18:1) (45). Thus, changes in acyl chain
composition of these typical lipids of the cytoplasmic leaflet as
they occur in PUFA-treated T cells (Table II) appear detrimen-
tal for the lipid order in the cytoplasmic leaflet of membrane
rafts, which is not stabilized by sphingolipids. In contrast, the
exoplasmic lipid leaflet of rafts seems much less prone to be
affected by fatty acyl unsaturation due to the presence of sphin-
golipids which greatly promotes the formation of a liquid-or-
dered state by interaction with cholesterol (26, 44, 46). In
conclusion, the considerable changes in fatty acyl composition
of raft lipids, particularly of those residing in the cytoplasmic
lipid leaflet, provide a biochemical basis that could underlie the
selective displacement of palmitoylated proteins from mem-
brane rafts in PUFA-treated T cells.
Src family kinases Lck and Fyn as well as the transmem-
brane adaptor protein LAT are concentrated in rafts due to
FIG. 2. Membrane subdomain distribution of [3H]palmitate-
label d proteins in fat y acid-treated T cells. A, fatty acid-treated
Jurkat T cells were labeled with [3H]palmitate as in Fig. 1 and lysed in
buffer containing 1% of the non-ionic detergent Brij-58. Rafts (Ra) and
soluble membrane fractions of intermediate (ID) and high density (HD)
were separated by sucrose density gradient centrifugation. Lck was
immunoprecipitated (IP) from rafts and soluble membrane fractions,
and aliquots were separated by SDS-PAGE for fluorography and im-
munoblotting, respectively. For PUFA-treated T cells (20:5), three in-
dependent examples are given showing membrane subdomain distribu-
tion of [3H]palmitate-labeled Lck and Lck protein. Positions of Lck
mig ating s p56 (black arrow) and p60 (gray arr w) are marked. B,
fatty acid-treated Jurkat T cells were labeled with [3H]palmitate fol-
lowed by membrane lysis and separation of rafts and soluble membrane
fractions as in A. LAT was immunoprecipitated, and aliquots were
separated by SDS-PAGE for fluorography and immunoblotting, respec-
ively. The position of LAT migr ting as p36/38 is marked by arrow-
head. Representative results from 2 to 4 experiments are shown. C,
quantitative assessment of experiments described in A and B. The
proportion of Lck and LAT protein (black columns) and [3H]palmitate-
labeled Lck and LAT (gray columns), respectively, which was displaced
from rafts and detected in soluble membrane fractions (ID, HD) is given
in percent (mean ! S.E.). Data from PUFA-treated cells (20:5) were
compared with corresponding data from control-treated cells (18:0); *,
p " 0.001 versus Lck protein in 18:0-treated T cells; †, p # 0.001 versus
[3H]palmitate-labeled Lck in 18:0-treated T cells; ‡, p " 0.05 versus LAT
protein in 18:0-treated T cells; §, p " 0.05 versus [3H]palmitate-labeled
LAT in 18:0-treated T cells.
Protein Displacement from Rafts by PUFAs 37339
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Figure 4 highlight a decrease in CD4+ T cells’ ability to proliferate. CD69+ is a 
glycoprotein involved in activation of CD4+ T cells and CD25+ is an important receptor 
for IL2, a growth factor for CD4+ T cells (Jang et al., 2013). 
The decrease in activation resulting from the high omega-3 levels in Fat-1 
transgenic mice would in turn affect cytokines produced by a normal mature CD4+ T 
cell. Figure 4 C shows levels of cytokines produced from wild type CD4+ T cells 
compared to Fat-1 transgenic mice’s CD4+ T cells. The expression of cytokines: IL-2, 
IL-4, and IFN-γ	  decreased	  with	  higher	  levels	  of	  omega-­‐3	  PUFAs	  as	  shown	  with	  Fat-­‐1	  





















Figure 4. Measurement of T cell activity in Fat-1 transgenic mice. A and B: Cells were 
left unstimulated with anti-CD3 antibody or stimulated with anti-CD3/anti-CD28 
antibodies. Cells were stained and analyzed via flow cytometry for percentage of CD69+ 
and CD25+. C: Cytokine levels of T cells were measured via ELISA. Figure taken from 
Jang, et al. (Jang et al., 2013) 
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Figure 1. CD4+ T-cell activation and cytokine production in vitro. CD4+ T cells were activated with plate-bound anti-CD3 antibody with
or without soluble anti-CD28 a tibody for 24 h. T- ell a tivatio was determined by flow cytometry analysis with anti-CD69 antibody
(A) and ti-CD25 antibody (B) and percentage of the cells expressing each molecule was calculated. (C) IL-2, IL-4, and IFN-! in the cell
culture media were measured with ELISA. (D) After 2 days of culture, cells were stimulated with PMA and ionomycin plus brefeldin A for
additional 4 h, and then intracellular cytokine content was evaluated. The percentages of cytokine-expressing cells are shown. Results of
three independent experiments are expressed as mean ± SEM. #p < 0.05, ##p < 0.01 versus WT.
Figure 2. CD4+ T-cell proliferation. The level of CD4+ T-cell proliferation was determined by flow cytomety analysis with CFSE labeling.
CFSE-labeled CD4+ T cells were stimulated by plate-bound anti-CD3 antibody with or without soluble anti-CD28 antibody for 4 days and
percentage of divided cells were analyzed by flow cytometry. Results of three independent experiments are expressed as mean ± SEM.
##p < 0.01 versus WT.
proximal signaling molecules, were detected in cells from
Fat-1 mice (Fig. 3B). In addition, we specifically analyzed
the NF-"B pathway, one of key signal transduction pathways
downstream of TCR. There was a complete inhibition of
TCR-triggered phosphorylation of p65 subunit and I"B-#
degradation in CD4+ T cells from Fat-1 mice (Fig. 3C). Since
NF-"B plays a central role in Th-cell activation, cytokine pro-
duction and survival [18, 19], the defect in Fat-1 transgenic
CD4+ T cells’ response to TCR stimulation is related to the
attenuated TCR signaling transduction.
C! 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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T cell signaling is disrupted by omega-3 PUFAs 
 Jang et al confirmed that omega-3 PUFAs reduce the activation and maturation of 
CD4+ T cells (Figure 4) and sought to explore the mechanisms of T cell activation that 
omega-3 PUFAs acted on. Figure 5 A and B shows Western Blots for levels of tyrosine 
phosphorylation and levels of phosphorylated signaling molecules. At certain time 
periods after stimulation of T cells with anti-CD3/anti-CD28 antibodies, levels of 
tyrosine phosphorylation and levels of phosphorylated Lck and Zap70 (signaling 
molecules) are decreased in Fat-1 transgenic mice compared to wild type (Jang et al., 
2013).  
Jang et al also investigated the NF-κB pathway, which is known to play a key role 
in T cell activation, cytokine production, and of survival. NF-κB expression involves the 
phosphorylation of the p65 subunit as well as degradation of IκB-α which are first 
triggered by T-cell receptor engagement (Jang et al., 2013). Figure 5C shows a Western 
Blot of the intermediates, p65 and IκB-α. The phosphorylation of the p65 subunit and the 
degradation of IκBα were both inhibited in the mice’s CD4+ T cells, which suggests an 




Figure 5. T cell signaling is affected by Omega-3 PUFAs. Western blots measured 
levels of tyrosine phosphorylation (A), levels of phosphorylated signaling molecules (B), 
and levels of phosphorylated p65 and IκBα	  expression	  (C)	  Figure	  taken	  from	  Jang,	  et	  al	  
(Jang	  et	  al.,	  2013). 
 
Costimulatory molecules in T cell activation are reduced with omega-3 PUFAs 
Brix et al sought to investigate how CD4+ T cells’ signal transduction was 
affected with high levels of omega-3 PUFAs. They analyzed spleen cells from mice fed a 
high omega-3 diet. One focus of their study was the costimulatory molecules of CD4+ T 
cells. Brix et al postulate that the “type and level of costimulatory molecule expression on 
activated CD4+ T cells are considered as key elements for the activation of adaptive 
immune responses.” Figure 6 shows an inverse linear correlation of CD4+ T cell division 
and CD28 expression. CD4+ T cell division was measured via flow cytometry where 
cells were stained with a PKH dye and cultured for 14 days with a measurement of the 
dilution of PKH left after the 14 days (Brix et al., 2010). CD28 expression was also 
measured via flow cytometry. CD28 is an important costimulatory molecule that is 
constitutively expressed in naïve T cells and helps stimulate the production of IL-2 (Brix 
6 H.-Y. Jang et al. Mol. Nutr. Food Res. 2013, 00, 1–11
Figure 3. TCR-mediated signal transduction. CD4+ T cells isolated from WT or Fat-1 mice were stimulated with plate-bound anti-CD3 and
soluble anti-CD28 for indicated periods. Cells lysates were immunoblotted with antibodies against pTyr (A), p-LCK, LCK, p-Zap70, and
Zap70 (B) or p-p65, p65, and I!B" (C). Similar results were obtained from three independent experiments.
3.3 Fat-1 expression suppresses T-cell
differentiation in vitro
To address whether Fat-1 expression affects CD4+ T-cell
differentiation into Th1 or Th2, we cultured CD4+ T cells
from WT and Fat-1 mice under Th1 or Th2 polarization
condition for 4 days. IFN-# and IL-4, hallmark cytokines of
Th1 and Th2 differentiation, respectively, were measured by
intracellular cytokine staining. CD4+ T-cell differentiation
into either Th1 or Th2 cells were partially suppressed in CD4+
T cells from Fat-1 mice as compared with those of WT CD4+
T cells (Fig. 4A). Real-time RT-PCR analysis of Th1/Th2 cy-
tokines also revealed that elevated n-3 PUFA in Fat-1 mice
inhibited Th-cell differentiation (Supporting Information
Fig. 2). Since STAT-1 and STAT-6 play an important role
in Th-cell differentiatio into Th1 and Th2, respectively, we
evaluated the effect of Fat-1 expression on the activation of
these signaling molecules. As shown in Fig. 4B, tyrosine
phosphorylation of STAT-1 by IL-12 was slightly reduced,
but STAT-6 activation triggered by IL-4 was markedly atten-
uated by elevated n-3 PUFA in Fat-1 mice. These results in-
dicate that Fat-1 expression not only suppresses CD4+ T-cell
activation/proliferation but also modulates CD4+ T-cell dif-
ferentiation into Th1 and Th2.
3.4 Fat-1 mice are protected from OVA-induced
allergic airway inflammation
Our in vitro experiments revealed that Fat-1 expression
on CD4+ T cells introduced T-cell intrinsic defects in
activation, proliferation, and differentiation. We, therefore,
examined whether Fat-1 mice are less susceptible to CD4+
T-cell-mediated asthmatic injury. We used OVA-induced al-
lergic airway inflammation as a murine model of human
asthma (Supporting Information Fig. 3). Following OVA
immunization and aerosol challenge, we assessed the lungs
for inflammatory cell infiltration by analyzing cells in BALF.
While OVA inhalation significantly increased inflammatory
cells in BALF from WT mice, there was a significant reduc-
tion in the total number of inflammatory cells in Fat-1 mice
(Fig. 5A). We further analyzed the types of immune cells
infiltrated into the lung by differential counts of BALF cy-
tospin preparations. The reduction in the total number of
the inflammatory cells infiltrated in the lung was largely
attributed to a remarkably lower number of eosinophils in
Fat-1 mice. Cells in BALF from control mice were mostly
macrophages, whereas over 95% cells in BALF from WT mice
with OVA immunization and challenge were eosinophils
and lymphocytes. BALF from Fat-1 mice contained a much
lower percentage of eosinophils and lymphcoytes but a higher
percentage of macrophages as compared with that of WT
mice. Consistently, histological examination of lung tissues
revealed intense e sinophilic inflammation surrounding the
bronchi and vessels in the lungs of WT mice while Fat-1 mice
had almost no inflammation (Fig. 5B).
Since bronchiolar mucin accumulation is one of the im-
portant features of chronic asthmatic response in patients
[20], we evaluated the amount of mucin produced from
bronchial goblet cells. Hyperproliferation of mucus-secreting
goblet cells was detected in asthmatic WT mice by Periodic
Acid-Schiff staining (Supporting Information Fig. 4). How-
ever, airway epithelial mucin levels were significantly reduced
in Fat-1 mice. Additionally, measurements of serum IgE
revealed a markedly less OVA-specific IgE in Fat-1 mice as
compared with WT mice (Fig. 5C). These results indicate that
Fat-1 mice are protected from allergen-induced airway in-
flammation by suppressing eosinophil recruitment and IgE
production.
3.5 Fat-1 expression reduces inflammatory
cytokines and eotaxin in BALF and lung tissues
Since Fat-1 expression suppressed allergen-induced airway
inflammation and mucin production in the airway, we next
C! 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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et al., 2010). Figure 6 shows that the lower CD28 expression in high omega-3 PUFA 
spleen cells correlated with lower T cell division. 
Brix et al also measured levels of the costimulatory molecule, inducible 
costimulator (ICOS), which is dependent on CD28 signaling. Flow cytometry analysis in 
Figure 7 showed consistently lower levels of ICOS compared to mice fed a high saturated 
fat diet (Brix et al., 2010).  
Collectively, the results from the aforementioned experiments suggest that 
omega-3 PUFAs negatively affect mechanisms involved in CD4+ T cell growth and 
maturation. Through alteration of the plasma membrane organization of CD4+ T cells, 
omega-3 PUFAs can modulate allergic responses that involve these T cells such as 
CMPA. 
Figure 6. Correlation of T cell division 
and CD28 expression. T cell division and 
CD28 expression on viable spleen CD4+ T 
cells were measured through flow cytometry. 
Mice were fed an omega-3 PUFA diet or a 
saturated fat diet. Figure taken from Brix, et al 

















Data for CD4+ T cells from MLNs resembled those from
SPL (data not shown). In line with this, an inverse corre-
lation was found between the percentages of CD28-posi-
tive cells and the cell division for each DC treatment and
diet group (Fig. 4c), indicating again that lack of CD28
responsiveness might explain the lower proliferation abil-
ity of n-3 PUFA-rich CD4+ T cells. To test if the differ-
ences in CD28 expression on CD4+ T cells after co-
culture with differentially primed DC were caused by
changes in B7 expression on DCs, we performed correla-
tion analyses between CD28 expression levels versus
CD80 and CD86 expression levels on DCs (Fig. 4d). No
significant correlation was found for CD28 versus CD86,
whereas if adjusted for diet treatment, a significant corre-
lation was found for CD28 versus CD80 (P = 0!048), but
for the n-3 PUFA group only, if not adjusted. To study
the effect of enhancing the dietary intake of n-6 PUFAs,



















































































Dietary FA: P = 0·0088







































































































































Figure 4. Proliferation of CD4+ T cells depends on the dendritic cell (DC) signal strength and the T-cell responsiveness towards CD28 signalling.
(a) Spleen (SPL) CD4+ T cells were isolated from BALB/c mice fed either the n-3 polyunsaturated fatty acid (PUFA) or the saturated fatty acid
(SFA) diet for 14 days, labelled with PKH and cultured at 105 cells per well with grading doses of bacteria-stimulated DCs, stimulated as
described in Fig. 3. After incubation for 5 days, flow cytometry was performed to examine the dilution of PKH in order to assess CD4+ T-cell
divisions. The percentages of T-cell divisions were determined as described in Fig. 1b. Each data point represents the mean ± standard deviation
(SD). The data represent three experiments. The number given above each proliferation curve indicates the slope of the curve (· 10)3), as analy-
sed by linear regression analysis. (b) SPL CD4+ T cells were co-cultured with in vitro-stimulated DC (at a ratio of 10:1, cultured as described in
Fig. 3) for 5 days, and then analysed for CD28 expression by flow cytometry, gated on viable CD4+ T cells. The data are mean + SD from two
experiments. (c) Inverse linear correlation between the percentage of CD28-positive CD4+ T cells (from Fig. 4b) and the cell-division ability for
cells cultured at the DC : T-cell ratio of 1:10 (Fig. 4a). Linear regression lines are shown for both dietary groups: R2 (n-3 PUFA), 0!57; and R2
(SFA), 0!78. (d) Inverse linear correlations between CD28 expression on CD4+ T cells [expressed as median fluorescence intensity (MFI)] and
DC expression of CD80 and CD86 (from Fig. 3). Correlation coefficients, CD80: n-3 PUFA: r = )0!89, P = 0!012, SFA: r = )0!64, P = 0!14.
CD86: n-3 PUFA: r = )0!68, P = 0!11, SFA: r = )0!50, P = 0!27. (a,b) Differences in proliferation or percentage of CD28 expression between the
two dietary groups and the different DC stimuli were tested by two-way analysis of variance (anova) and Bonferroni’s post hoc test. P-values for
the effects of diets and DC stimuli on proliferation and CD28-positive cells are given in the text (a) or in the figure (b). No interaction between
the diets and the DC stimuli was observed.
! 2009 Blackwell Publishing Ltd, Immunology, 129, 338–350 345



















Figure 7. ICOS expression with omega-3 PUFAs. Spleen CD4+ T cells from mice with 
an omega-3 PUFA diet or a saturated fatty acid diet were analyzed and stained with 
fluorescin-conjugated antibodies. ICOS expression on viable CD4+ T cells was 
measured via flow cytometry. Figure taken from Brix, et al (Brix et al., 2010). 
 
Discussion 
 Interruption of the plasma membrane organization of cells can have numerous 
effects on cell function. Researchers describe omega-3 PUFAs as modifying “the 
compressibility, phospholipid flip-flop, acyl chain packing, elasticity, and lipid domain 
formation” of the plasma membrane of cells (Shaikh et al., 2012). Such changes take 
place in the immunological synapse of a CD4+ T cell and an antigen-presenting cell as 
omega-3 PUFAs incorporate into the lipid rafts of T cells and disrupt the molecular 
organization, thus affecting signaling within the cell (Shaikh et al., 2012). CD4+ T cells 
are good targets for modulating allergic diseases like Cow’s Milk Protein Allergy as they 
produce the inflammatory cytokines IL4, IL5, and IL13, as well as mast cells and IgE 
(Jang et al., 2013).  
Omega-3 PUFAs, through the modification of lipid rafts, affect different 
in which the dietary content of n-6 PUFAs was increased
to 40 wt%, while keeping the dietary n-3 PUFA content
at 2 wt% (and the SFA content similar to that of the n-3
PUFA group). However, no further effects in regard to
the cellular FA composition in CD4+ T cells was
observed, and the cell proliferation was similar to that of
the SFA group (data not shown).
CTLA-4 and ICOS levels depend on n-3 PUFA
content and DC signal strength
To evaluate the significance of the signal transmission
capability in CD4+ T cells on costimulatory molecule
expression, induced through DCs, in the CD4+ T cells
harbouring different n-3 PUFA levels, we measured the
expression of CTLA-4 and ICOS upon activation with the
differentially primed allogenic DCs.
The percentage of ICOS-positive cells was shown to
depend on both the DC signal and the cellular PUFA
ratio, with the lowest percentages observed in cells with
the highest n-3 PUFA content (Fig. 5a). Interestingly, we
found an inverse correlation between the expression level
of CD40 on DCs and the percentages of ICOS-positive
SPL and MLN CD4+ T cells (Fig. 5b, data not shown for
MLN), thus indicating an indirect link between CD40L
and ICOS expression on CD4+ T cells.
With respect to CTLA-4, we measured the con-
tents of cell-surface protein and intracellular protein
simultaneously, in order to account for the total pool of
CTLA-4, as CTLA-4 molecules are recognized to be
50
Dietary FA: P < 0·0001
DC stimulus: P < 0·0001
Dietary FA: P < 0·0001




































































































































































Figure 5. The expression level of the T-cell costimulatory molecules inducible costimulator (ICOS) and cytotoxic T-lymphocyte antigen-4 (CTLA-
4) is dependent on th CD40 leve on dendritic cells (DCs), and is reduced in n-3 polyunsaturated fatty acid (PUFA)-rich CD4+ T cells. Spleen
(SPL) CD4+ T cells, derived from mice fed diets high in n-3 PUFAs or saturated fatty acids (SFAs), were co-cultured with in vitro-stimulated DCs
(at a ratio of 10:1, DCs were cultured as described in Fig. 3) for 5 days, stained with fluorescein-conjugated antibodies and analysed by flow cytom-
etry with gating of viable CD4+ T cells. (a) The percentage of ICOS- and CTLA-4-positive cells. Data are mean + standard deviation (SD) from two
experiments. Differences in expression of T-cell surface markers between the two dietary groups and the different DC stimuli were tested by two-
way analysis of variance (anova) and Bonferroni’s post hoc test. P-values are given in the boxes. No interaction between the diets and the DC stim-
uli was observed. (b) Linear regression analysis between CD40 or CD86 expression on DCs (Fig. 3) and mean percentage of ICOS-positive or
CTLA-4-positive SPL CD4+ T cells (Fig. 5a). Difference between dietary treatments, ICOS versus CD40: P < 0!0001, CTLA-4 versus CD86:
P = 0!0002 (from linear regression analysis). Spearman’s correlation coefficients are given below (n-3 PUFA) or above (SFA) the regression lines.
346 ! 2009 Blackwell Publishing Ltd, Immunology, 129, 338–350
S. Brix et al.
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components of CD4+ T cells. Altering lipid rafts in the plasma membrane affects signal 
cascades downstream from the membrane and this was shown in the decrease of tyrosine 
phosphorylation as well as the downregulation of the NF-κB pathway (Jang et al., 2013). 
Costimulatory molecules expressed on the surface of CD4+ T cells were also 
affected by omega-3 PUFAs. Brix et al state that CD28 and T-cell receptor signaling is 
dependent on a number of signaling proteins, including LAT, which is known to be 
decreased in the omega-3 disruption of plasma membranes (see Figure 3). They also state 
that CD28 is targeted to the lipid raft during T cell activation, which makes it susceptible 
to omega-3 incorporation. Decreases in CD28 and T-cell receptor signaling reduce the 
responsiveness of CD4+ T cells and affect other costimulatory molecules (such as ICOS) 
that are important for the regulation of T cells (Brix et al., 2010).  It has been shown in a 
previous study that a decrease in ICOS decreases inflammation as well as reduces serum 
IgE production (Brix et al., 2010). Inflammation and IgE levels are both important 
characteristics in allergic diseases, especially in CMPA.  
Modulation of the immune system response in allergic diseases, such as CMPA, 
by nutritional intervention holds much promise. Incorporation of omega-3 PUFAs into 
the plasma membrane affects key signaling pathways in CD4+ T cells. The use of omega-
3 PUFAs has already been tested in clinical trials. Such trials include: the observance of 
maternal omega-3 supplementation on allergic responses of neonates and the study of fish 
oil supplementation on 6 month old infants with high risks for allergic hypersensitivity 
(Klemens, Berman, & Mozurkewich, 2011)(D’Vaz et al., 2012). Such studies show 
promising results that reflect those seen in in vitro and animal studies. Further studies of 
omega-3 PUFAs may lead to treatments for many allergic diseases, not just CMPA. 
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Clinical Case Study 
Chief Complaint 
 Kevin Westbrook is a 3 week old, African American male infant brought in by his 
parents to the physician’s office after three days of diarrhea with small streaks of blood.  
History of Present Illness 
 Kevin’s mother reports that Kevin primarily breast feeds around every 3 hours, 
supplementing with Enfamil Premium for Newborns formula as needed, using the 
recommended ratio: 2 fl oz of water to one scoop of powder formula. Kevin has bowel 
movements around 5-8 times a day. In the last three days however, Kevin has had more 
frequent bowel movements with wet stools containing small streaks of blood. His mother 
is unsure of the number of wet diapers over the last two days. She reports frequent and 
multiple spit ups, but no vomiting. No change in appetite has been apparent. Kevin’s 
mother also reports seeing rashes on his chest, arms, and a little on the legs, but says she 
recently just tried a new brand of laundry detergent that may be causing his clothes to 
irritate his skin. Kevin has been healthy and has not been on any medications or 
antibiotics leading up to this visit. The mother denies any coughing or nasal congestion. 
Kevin has had no recent sick contacts.  
Medical History 
Birth History: Kevin’s mother had an uncomplicated pregnancy with a C-section 
due to failure to progress. Information obtained from his birth records indicate there were 
no complications during delivery. Kevin was born at full term, 40 weeks, weighing 7.45 
lbs, with a height of 20.23 inches. Kevin received an APGAR score of 9 at one minute 
after birth and at five minutes after birth: he received a 2 for his breathing, a 2 for his 
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heart rate being greater than 100 beats per minute, a 2 for his muscle tone, a 1 for his 
grimace response, and a 2 for having a pink color throughout his body.  
Immunizations: Hepatitis B at birth 
Other: Parents deny any significant medical issues for Kevin. 
Social History 
Kevin’s mother works from home as a Mary Kay consultant, managing her own 
business and reports having low-stress. Kevin’s father works in the Accounting 
Department at one of the local casinos. Kevin is the second of two boys, his older sibling 
being 4 years old. Parents do not smoke and there are no pets in the house. 
Family Medical History 
Kevin’s family history includes heart disease and high cholesterol from his 
paternal grandfather and breast cancer from his maternal grandmother. Kevin’s older 
brother has no significant medical issues, is up to date on all immunizations, and is 
currently being taken to a local day care twice a week.  
Physical Exam 
Vital Signs and Measurements Length: 21.73 inches 
Weight: 8.45 lbs 





General Appearance Appears irritable but still conscious and alert. Patient is 
fussy when examination is attempted. 
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HEENT Skull is symmetrical. Anterior fontanelle is open and flat. Pupils 
are equal and reactive to light. Red reflex bilaterally. Left and right 
TM and canal clear. Bony landmarks and light reflex present in 
both ears. No septal deviation or nasal polyps. MM slightly dry but 
throat is clear with no erythema or exudates. 
Neck  No neck masses, no enlarged nodes noted, no thyromegaly. 
Chest/Lungs Clear to auscultation bilaterally. No wheezing and no retractions. 
Heart Regular rate and rhythm with no murmurs. Normal S1 and S2. 
Abdomen Soft with no masses and abdomen is non-distended. Umbilicus has 
detached with no swelling or redness in the area. Regular bowel 
sounds are present. No organomegaly noted. 
Genitourinary Descended testes bilaterally with healing circumcision site. 
Extremities Fingers and hands appear normal. Hips symmetrical with full range 
of movement. Palpable femoral and brachial pulses. Legs are 
symmetrical and feet appear normal. 
Spine and Back Straight spine with no deformities. 
Neurologic  Patient is alert and attentive. Responsive to light and noise. 
Primitive reflexes appear intact.  Development appears normal. 
Skin Skin does not feel too warm or too cold to the touch but feels 
slightly dry. Skin color is normal but red, scaly rashes can be seen 
on the bends of the elbows, the upper chest, and some spots on the 
legs. Rash resembles what is pictured. Skin turgor is slightly 





Figure 8. Pediatric atopic dermatitis (eczema). Figure adapted from Paller et al. 













 Results Normal Values 
RBC Count 4.5 x 106/μl (3.6-6.2) 
Hemoglobin 14 g/dL (12.5-20) 
Hematocrit 45% (39-63) 
MCV 90 fL (86-124) 
MCH 33 pg (28-40) 
MCHC 32 g/dL (28-38) 
WBC Count 10,000/	  μl (5,000-20,000) 
Lymphocyte 36% (25-37) 
Monocyte 7% (0-9) 
Eosinophil 2.5% (0-2) 
Basophil 0.5% (0-1) 
Absolute Neutrophil 19.2 x 103/	  μl (6.0-23.5) 




Electrolytes     Blood Gases 
 Results Normal Values  Results Normal Values 
Sodium 133 meq/L (133-146) pH 7.40 (7.35-7.45) 
Potassium  3.8 meq/L (3.7-5.9) pCO2 38 mmHg (34-46) 
Chloride 98 meq/L (98-106) pO2 92 mmHg (80-100) 
Bicarbonate 25 meq/L (23-28) O2 Saturation 98% (>95%) 
 
Urinalysis 
 Results Normal Values 
pH 6.0 5.0-7.0 
Urine osmolarity 600 mOsm/L 50-600 mOsM/L 
Urine specific gravity 1.020  (1.005-1.030) 
RBC 1/hpf <2/hpf 
WBC 1/hpf <2/hpf 
RBC Casts 0/hpf 0/hpf 
Negative for bilirubin, blood, ketone, leukocytes, nitrites, proteins  
 








Liver Function Tests    
 Results Normal Values 
AST 23 IU/L 0-60 IU/L 
ALT 20 U/L 0-50 U/L 
GGT-P 24 IU/L 0-50 IU/L 
ALP 85 IU/L 75-375 IU/L 
 
Stool Culture    Rotavirus Assay- negative 
Microscopy results indicate presence of fecal 
leukocytes 
Lactose Hydrogen Breath Test <5 ppm above basal values over 2 hour period 
Abdominal Ultrasound  No masses. Negative for intussusception.  
 
Figure 9. Normal abdominal ultrasound. Image adapted from Hayden et al. 
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Fig. 1. Normal gastroesophageal
anatomy. A Images obtained along
the long axis of the distal antrum
(A) in the relaxed/closed state
demonstrate the thin, hypoechoic
outer layer of the muscularis pro-
pria (M). The other mural layers
can be identified, although the ap-
posing mucosal layers cannot be
well evaluated in this closed state.
Body of stomach (S). B Distal an-
trum (A), pylorus (P), and duode-
nal bulb (D) after fluid has been
administered. The mural layers can
now be well defined: innermost
echogenic mucosa (Mu), the thin,
hypoechoic layer of lamina pro-
pria/muscularis mucosa (Lp), the
echogenic submucosa and inter-
face between the submucosa and
muscularis propria (S), and hypo-
echoic outer layer of muscularis
propria (M). C The abdominal
esophagus (arrows). Stomach (S)
and left lobe of liver (L).
Fig. 2. Gastroesophageal reflux.
Image along the long axis of the
distal esophagus and gastroesopha-
geal junction demonstrates reflux
(white arrow) of fluid from the
stomach (S). Left lobe of liver (L)
and abdominal esophagus (E).
Gastroesophageal Reflux
Primary gastroesophageal reflux (GER) is a common
disorder in infants and children, although in the great
majority of cases, it probably constitutes a ‘‘physiolog-
ical’’ event [7]. The abdominal esophagus demonstrates
progressive lengthening as the infant grows, normally
reaching optimal length by 18 months of age [9]. Nev-
ertheless, GER can still lead to significant complications
in the infant and young child (e.g., failure to thrive,
esophagitis, chronic blood loss, esophageal stricture, re-
current pneumonia, reactive airway disease, and possi-
bly apnea of infancy) [7].
A reflux episode is characterized sonographically by
(a) opening of the lower esophageal sphincter, (b) gas-
tric contents moving up the distal esophagus (Fig. 2),
(c) to-and-fro movement of these contents in the distal
esophagus, (d) clearance of the esophagus of refluxed
material by peristalsis, and (e) closure of the lower
esophageal sphincter [7]. Furthermore, the examiner is
able to define the abdominal esophagus in vivo (Fig.
1C) and potentially predict those patients who are at risk
for esophagitis. The patients who demonstrate abnormal
shortening of the abdominal esophageal canal are more
likely to have significant GER and the potential for eso-
phagitis [7–9]. The length of the canal, as previously
noted, varies significantly with age, normally increasing
from about 20 mm in the newborn to 30–35 mm at 2–
4 years of age [9].
Gastric Outlet Obstruction
Hypertrophic pyloric stenosis consists of hypertrophy
of the outer circular muscle of the pyloric canal, prob-
ably secondary to overactivity or prolonged spasm of
the antropyloric muscle [12]. Sonography has proven
highly sensitive and specific in its diagnosis by virtue
of the ability to visualize directly the pyloric muscle.
Various diagnostic parameters have been examined, in-
cluding muscle thickness, antropyloric length, pyloric




Skin Prick Test   Cow milk 5 mm  (<6 mm) 
     Egg  4 mm  (<7 mm) 
     Peanut  4 mm  (<8 mm) 
Specific IgE RAST   0.32 U/ml (<0.35 U/ml) 
Diagnosis 
 Kevin’s electrolyte levels are on the low normal end and his slightly dry MM, 
slightly dry skin, and reduced skin turgor suggests he has mild dehydration from his 
episodes of diarrhea. Results from stool cultures indicate Kevin is not suffering from a 
rotavirus but his stool does have some leukocytes. Lactose intolerance is eliminated after 
a normal result is obtained from a lactose hydrogen breath test. An abdominal ultrasound 
appeared normal, ruling out intussusception. A food allergy was now highly suspected 
but Kevin’s wheal diameters were within normal ranges for cow’s milk, egg, and peanut. 
A specific IgE RAST was also performed, which yielded normal results.  
 Since the mother reports multiple, frequent spit-ups, indicative of 
gastroesophageal reflux, as well as diarrhea with blood streaks in the stool, along with the 
observed rashes, indicative of atopic eczema, a tentative diagnosis of Cow’s Milk Protein 
Allergy (CMPA) was made. Since lab results were negative for milk and IgE levels, Non-
IgE CMPA was considered. To confirm the diagnosis, Kevin’s mother was placed on a 
strict no milk diet for two weeks. Kevin was also given a hypoallergenic, extensively 
hydrolyzed formula to supplement breast-feeding as needed. Kevin’s symptoms 
improved in that time. To ensure the correct diagnosis was made, the mother was put 
back on a milk diet and Kevin’s previous formula was used for supplementing 
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breastfeeding for one week. In this week, Kevin’s diarrhea returned with the formation of 
rashes on his skin beginning again. Kevin’s diagnosis of Non-IgE mediated Cow’s Milk 
Protein Allergy was confirmed. 
Treatment 
 Kevin is put on a strict no milk diet. Kevin’s parents are given a list of extensively 
hydrolyzed and amino acid based formulas appropriate for his diet. Kevin’s mother is 
given a list of foods that contain milk that should be avoided if she chooses to continue 
breastfeeding. She is advised to see a dietitian to help her choose a well-balanced, 
nutritious diet that will keep her healthy while breastfeeding. Kevin’s parents are advised 
to reintroduce cow’s milk after 6 months of avoidance to see if tolerance has been 
achieved. The physician, dietitian, and family will undertake a course of action if, at that 
time, symptoms reoccur. Kevin’s parents will most likely be advised to reintroduce cow’s 
milk when Kevin is around 12 months old to check again for tolerance. For Kevin’s 
atopic eczema, he is prescribed a 2.5% hydrocortisone cream, to be applied once a day 
for two weeks. Kevin’s dehydration is mild enough that this does not warrant rehydration 
with IV fluids, but he will need to be monitored closely for signs that his dehydration is 
worsening (i.e. lack of urination, lack of tears, loss of skin turgor). 
Prognosis 
 Over half of infants who are diagnosed with Cow’s Milk Protein Allergy develop 
a tolerance within the first two years of life. Kevin is expected to follow this trend. If he 
displays adverse reactions to cow’s milk after 6 months and after 12 months of age, he 
will be placed on a no milk diet again and will be tested for tolerance at 24 months of 





 Kevin’s parents will be given a list of proper alternate formulas appropriate for 
his feeding (Figure 10). They will also be given a list of foods that contain milk (Figure 
11), which he should avoid as he transitions to solid foods in the next several months. 
Kevin’s mother will be referred to a dietitian who will help her manage a no milk diet if 
she chooses to continue breastfeeding. Kevin’s mother is assured that Kevin’s 
development will not be negatively impacted if she does forego breastfeeding. Kevin’s 
growth and response to this diet will be monitored during his upcoming visits for his 
immunizations. Before his 6-month scheduled immunizations, he will be reintroduced to 
milk so his response can be observed at the time of his visit. This will be repeated at the 
12-month mark if there is an adverse response. 
 
 
Figure 10. Formula options for patient. Figure adapted from UptoDate.com. 
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Hypoallergenic formula options for infants with dietary protein-induced
conditions
Extensively hydrolyzed casein protein
Similac Alimentum (Abbott)
Enfamil Nutramigen (Mead Johnson)




Neocate Infant DHA and ARA (Nutricia)
Puramino (previously known as Nutramigen AA) (Mead Johnson)
Courtesy of Alan Lake, MD.





















Figure 11. Foods 
containing milk to avoid. 
Figure adapted from 
UptoDate.com. 
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Whey protein hydrolysate
Yogurt





Lactic acid starter culture and other bacterial cultures





All FDA-regulated manufactured food products that contain milk as an ingredient are required by US law
to list the word "milk" on the product label.
Copyright © 2010 The Food Allergy & Anaphylaxis Network. Used with permission.
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How to read an ingredient label for a milk-free diet
Avoid foods that contain milk or any of these ingredients:

















Milk (in all forms, including condensed, derivative, dry, evaporated, goat's milk and milk from other





Sour cream, sour cream solids
Sour milk solids
Tagatose
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